Ayahuasca : Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness Jonathan Hamill, Jaime Hallak, Serdar M. Dursun and Glen Baker Current Neuropharmacology, 2019, 17, 108-128. Doi : 10.2174/1570159X16666180125095902 Abstract Background : Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) andleaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experiences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use [...]
Lire la suiteThe Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325 Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]
Lire la suiteThe Therapeutic Potentials of Ayahuasca in the Treatment of Depression Fernanda Palhano-Fontes, Joao C. Alchieri, Joao Paulo M. Oliveira, Bruno Lobao Soares, Jaime E. C. Hallak, Nicole Galvao-Coelho and Draulio B. de Araujo Chapter 2, in B. C. Labate and C. Cavnar (eds.), "The Therapeutic Use of Ayahuasca", Springer-Verlag Berlin Heidelberg, 2014 Doi : 10.1007/978-3-642-40426-9_2, Abstract Major depressive disorder (MDD) is generally classified as a mood disorder with a profound effect on the individual’s behavior and quality of life. According to the World Health Organization, in about 20 years, depression will be the disorder with the most significant repercussions, both socially and economically. Despite [...]
Lire la suitePsilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575 Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]
Lire la suiteBIBLIOGRAPHIE : Beta-Carbolines Harmine, Harmane, Harmaline, Nor-harmane, Harmol, Harmalol, Tetrahydroharmine β-Carbolines et Thérapeutique en Psychiatrie, p. 6. (cf également Bibliographie : Peganum harmala, p. 7 ci-dessous, et Bibliographie : Amanita muscaria, et Bibliographie : Ayahuasca) Dr Christian SUEUR, GRECC, décembre 2019.
Lire la suiteIACM-Bulletin du 06 Décembre 2019 Science/Homme: Le cannabis riche en CBD pourrait être utile dans l'autisme Science/Homme: Le cannabis peut être utile dans le traitement de l'endométriose Science/Homme: Un extrait de chanvre riche en CBD peut réduire l'utilisation d'opiacés chez les patients souffrant de douleur chronique États-Unis: Un Comité de la Chambre des Représentants adopte un projet de loi historique visant à décriminaliser le cannabis Royaume-Uni: 20 000 patients bénéficieront d'un essai de cannabis médical En bref Un coup d'œil sur le passé Science/Homme: Le cannabis riche en CBD pourrait être [...]
Lire la suiteModulation of Social Cognition via Hallucinogens and “Entactogens” Katrin H. Preller and Franz X. Vollenweider Frontiers in Psychiatry, décembre 2019 doi: 10.3389/fpsyt.2019.00881 Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning also represent a core aspect of many psychiatric disorders. Yet, despite its significance, deficits in social cognition skills are insufficiently targeted by current treatments. Hallucinogens and entactogens have been shown to have the potential to modulate social processing. This article reviews the literature on the influence of hallucinogens and entactogens on social processing in controlled experimental studies in humans and elucidates the underlying neurobiological and neuropharmacological mechanisms. Furthermore, [...]
Lire la suiteCannabis Oil : chemical evaluation of an upcoming cannabis-based medicine Luigi L. Romano, Arno Hazekamp Cannabinoids, 2013, 1, (1), 1-11 © International Association for Cannabinoid Medicines Abstract Concentrated cannabis extracts, also known as Cannabis oils because of their sticky and viscous appearance, are becoming increasingly popular among self-medicating patients as a claimed cure for cancer. In general, preparation methods for Cannabis oils are relatively simple and do not re-quire particular instruments. The most well-known example of such a product is called ‘Simpson oil’. The purpose of the extraction, often followed by a solvent evaporation step, is to make canna-binoids and other beneficial components such as [...]
Lire la suiteMolecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites Chun Yang, Jianjun Yang, Ailin Luo and Kenji Hashimoto Translational Psychiatry, 2019, 9, 280 doi : 10.1038/s41398-019-0624-1 Abstract Although the robust antidepressant effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although (R)-ketamine is a less potent NMDAR antagonist than (S)-ketamine, (R)-ketamine has shown more marked and longer-lasting antidepressant-like [...]
Lire la suiteCBD Isolates Vs. Full-Spectrum CBD Martin A. Lee On February 22, 2015 https://www.projectcbd.org/science/cbd-isolates-vs-full-spectrum-cbd A groundbreaking study has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule CBD. A groundbreaking study from Israel has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule cannabidiol (CBD). Published in the journal Pharmacology & Pharmacy (Feb. 2015), the article directly challenges one of the sacred cows of Big Pharma and the medical-industrial complex—the notion that “crude” botanical preparations are inherently low grade and less effective than pure, single-molecule compounds. Entitled “Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis [...]
Lire la suite